Chemotherapy-induced peripheral neuropathy (CIPN) considerably impairs cancer patients’ QOL, and may lead to discontinuation of drug treatment of cancer. Currently, there is no effective strategy against CIPN. Therefore, it is an urgent issue to develop clinically available drugs that prevent or treat CIPN. We have shown that high mobility group box 1 (HMGB1), a damage-associated molecular pattern (DAMP) molecule, plays an essential role in the development of CIPN. Most interestingly, thrombomodulin α, approved as a medicine for treatment of disseminated intravascular coagulation (DIC) in Japan, causes thrombin-dependent degradation of extracellular HMGB1 that is released in response to chemotherapeutics, and prevents CIPN. Thus, we expect that targeting HMGB1 or its receptors would lead to prevention of CIPN in cancer patients in near future.
CITATION STYLE
Kawabata, A., Tsubota, M., Sekiguchi, F., & Tsujita, R. (2019). HMGB1 as a target for prevention of chemotherapy-induced peripheral neuropathy. Folia Pharmacologica Japonica, 154(5), 236–240. https://doi.org/10.1254/fpj.154.236
Mendeley helps you to discover research relevant for your work.